Published by Josh White on 19th September 2023
(Sharecast News) - Life sciences company Avacta Group announced the successful completion of its sixth dose escalation cohort in the ALS-6000-101 phase one clinical trial on Tuesday, assessing the safety and tolerability of the drug, AVA6000.
URL: http://www.digitallook.com/dl/news/story/33779449/...